The Biologics News and Reports Portal

Show Cart

All Products

Results 61 - 80 of 188

May 2018 TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

2,150.00 €

Mar 2018 Competitor Analysis: CDK9 and Mcl-1 Inhibitors

200.00 €

Mar 2018 Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

80.00 €

Jan 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

2,300.00 €

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

450.00 €

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

3,080.00 €

4,400.00 €

(Discount: 30.00%)

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

300.00 €

Jun 2017 mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

2,250.00 €

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

150.00 €

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

400.00 €

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

70.00 €

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

200.00 €

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

2,150.00 €

Dec 2016 Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

800.00 €

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

1,140.00 €

1,900.00 €

(Discount: 40.00%)

Shopping cart

Cart empty

Latest report

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Featured Products

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Latest Target Pipeline

STING Agonists & Antagonists

Shopping cart

Cart empty

Latest report

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Featured Products

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

All Products

Jun 2018 Competitor Analysis: hTERT-Targeted Immunotherapy

Jun 2018 Competitor Analysis: WT1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: PRAME-Targeted Immunotherapy

May 2018 Report Package: TCR-Based Antibody and T-Cell Immunotherapy

May 2018 Competitor Analysis: Survivin-Targeted Immunotherapy

May 2018 TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Mar 2018 Competitor Analysis: CDK9 and Mcl-1 Inhibitors

Mar 2018 Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

Jun 2017 mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Dec 2016 Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing